Exclusive Summary

• - Mature plasma-derived category with no core patent lock; globally used for decades, allowing flexible market entry timing.
• - Addresses rigid demand for rapid reversal in warfarin-related major bleeding and urgent surgery, with an estimated 0.6–1.0 million such episodes globally per year and widespread off-label use in DOAC bleeds.
• - Listed on the WHO Essential Medicines List and recommended as first-line for VKA reversal by multiple guidelines; this product is a 3F profile (no FVII, contains FVIII), best suited to markets/indications accepting 3F-PCC.
• - Competition includes >10 brands (CSL, Octapharma, Takeda, etc.) plus national blood-center products; supply depends on plasma sourcing and tenders, enabling entry via price and reliable supply.
• - Versus costly specific antidotes (e.g., andexanet), PCC can save 50–90% of costs; a 30–40% discount vs originator PCCs is highly attractive to payers and hospitals.